CASI Pharmaceuticals Inc  

(Public, NASDAQ:CASI)   Watch this stock  
Find more results for NASDAQ:ENMD
-0.005 (-0.57%)
Real-time:   1:45PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.85 - 0.90
52 week 0.58 - 2.13
Open 0.90
Vol / Avg. 2,755.00/37,773.00
Mkt cap 26.25M
P/E     -
Div/yield     -
EPS -0.22
Shares 32.45M
Beta 1.63
Inst. own 7%
Mar 25, 2016
Q4 2015 CASI Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Nov 13, 2015
Q3 2015 CASI Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -110418.50%
Operating margin - -110356.00%
EBITD margin - -110153.00%
Return on average assets -82.11% -195.41%
Return on average equity - -360.91%
Employees 20 -
CDP Score - -


9620 Medical Center Dr Ste 300
ROCKVILLE, MD 20850-3396
United States - Map
+1-240-8642600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. Its product pipeline includes ENMD-2076, ZEVALIN, MARQIBO, CE Melphalan and 2ME2 (2-methoxyestradial). Its lead internal drug candidate is ENMD-2076 is a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ZEVALIN is indicated for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma. MARQIBO is indicated for the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia. Captisol Enabled melphalan is being investigated and is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. 2ME2 (2-methoxyestradiol) is an orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties under reformulation development.

Officers and directors

Wei-Wu He Ph.D. Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Ken K. Ren Ph.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Cynthia Wong Hu J.D. Chief Operating Officer, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Sara B. Capitelli CPA Vice President - Finance, Principal Accounting Officer
Age: 48
Bio & Compensation  - Reuters
Rong Chen M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Tak W. Mak Ph.D. Director
Age: 69
Bio & Compensation  - Reuters
Rajesh C. Shrotriya M.D. Director
Age: 71
Bio & Compensation  - Reuters
James Z. Huang Independent Director
Age: 49
Bio & Compensation  - Reuters
Franklin C. Salisbury Jr. Independent Director
Age: 59
Bio & Compensation  - Reuters
Y. Alexander Wu Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters